Goldline Pharmac

Which are the latest news on Goldline Pharmac?

Why is Goldline Pharmaceutical Ltd falling/rising?

As of 05-Sep, Goldline Pharmaceutical Ltd's stock price is at 39.16, down 4.25%, and has underperformed its sector. The stock is experiencing high volatility and is trading below all major moving averages, indicating a bearish trend and decreased investor participation.

As of 05-Sep, Goldline Pharmaceutical Ltd's stock price is falling, currently at 39.16, which reflects a decrease of 1.74 or 4.25%. The stock has underperformed its sector by 4.2% today and opened with a significant loss of 4.65%. Additionally, it reached an intraday low of Rs 34.13, marking a decline of 16.55%. The trading activity has been erratic, with the stock not trading on one day out of the last 20 days, and it has exhibited high volatility with an intraday volatility of 7.05%. <BR><BR>Moreover, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. There has also been a notable drop in investor participation, with delivery volume on September 3 falling by 95.69% compared to the 5-day average. These factors collectively contribute to the decline in Goldline Pharmaceutical Ltd's stock price.

What does Goldline Pharmac do?

Goldline Pharmaceutical Ltd markets pharmaceutical products and is classified as a Micro Cap company with a market cap of INR 39 Cr. It has a P/E ratio of 9.00 and a return on equity of 28.91%, but no recent sales or profit data is available.

Overview:<BR>Goldline Pharmaceutical Ltd is engaged in the marketing of pharmaceutical products and operates within the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History:<BR>Goldline Pharmaceutical Ltd was incorporated on August 2, 2004, as a private limited company and later converted into a public limited company on September 23, 2013. There is no recent sales or profit data reported.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 39 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 9.00<BR>Industry P/E: 37<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.60<BR>Return on Equity: 28.91%<BR>Price-to-Book: 2.76<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the peers of the Goldline Pharmac?

Goldline Pharmac's peers include Kabra Drugs, ANG Lifesciences, Rajnish Wellness, and others. Management risk varies from excellent to below average, with ANG Lifesciences showing the highest 1-year return at 20.93% and Murae Organisor the lowest at -72.86%.

Peers: Goldline Pharmac's peers are Kabra Drugs, ANG Lifesciences, Rajnish Wellness, Vivo Bio Tech, Murae Organisor, Roopa Industries, Vista Pharma, Chandra Bhagat, Sandu Pharma, and JFL Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Kabra Drugs and Roopa Industries, while Average management risk is found at Rajnish Wellness and Sandu Pharma. Below Average management risk is noted for ANG Lifesciences, Vivo Bio Tech, Murae Organisor, Vista Pharma, Chandra Bhagat, and JFL Life, and the rest. Growth is Excellent at Kabra Drugs and Roopa Industries, Good at Murae Organisor, Average at Rajnish Wellness and Sandu Pharma, and Below Average at ANG Lifesciences, Vivo Bio Tech, Vista Pharma, Chandra Bhagat, and JFL Life, and the rest. Capital Structure is Good at Sandu Pharma and JFL Life, Below Average at Kabra Drugs, ANG Lifesciences, Rajnish Wellness, Vivo Bio Tech, Murae Organisor, Roopa Industries, Vista Pharma, and Chandra Bhagat, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is ANG Lifesciences at 20.93%, while the lowest is Murae Organisor at -72.86%. Goldline Pharmac's 1-year return is not available for comparison. Additionally, peers such as Murae Organisor, Rajnish Wellness, Vivo Bio Tech, and Sandu Pharma have negative six-month returns.

How big is Goldline Pharmac?

Summary could not be generated.

As of 31st August, Goldline Pharmaceutical Ltd has a market capitalization of 39.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent quarterly performance data is unavailable, so there are no figures for Net Sales or Net Profit for the latest four quarters.<BR><BR>The latest annual period for the balance sheet is March 2026, with Shareholder's Funds reported at 14.25 Cr and Total Assets at 28.79 Cr.